STARR CHRISTOPHER M 4
4 · Monopar Therapeutics · Filed Jul 16, 2025
Insider Transaction Report
Form 4
STARR CHRISTOPHER M
Director
Transactions
- Exercise of In-Money
Common Stock
2025-07-14$0.01/sh+16,800$84→ 21,973 total - Exercise of In-Money
Stock Options
2025-07-14−16,800→ 0 totalExercise: $0.01Exp: 2026-04-04→ Common Stock (16,800 underlying) - Sale
Common Stock
2025-07-14$40.00/sh−16,800$672,020→ 5,173 total
Holdings
- 9,880(indirect: See Footnote)
Common Stock
Footnotes (4)
- [F1]This transaction involved a cash exercise of stock options.
- [F2]The shares were sold in multiple transactions at prices ranging from $40.00 to $40.25, inclusive. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
- [F3]9,880 shares of common stock held by the Christopher M. Starr and Sheri L. Starr Revocable Trust over which Dr. Starr serves as Trustee
- [F4]Reflects options to purchase up to 16,800 shares of common stock granted to Dr. Starr on April 4, 2016, for his services as a director of Monopar Therapeutics. The options vested 6/12ths upon the grant date and 3/12th every 6 months thereafter.